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1. Introduction 
Endometriosis is classically defined as the growth of endometrial glands and stroma at 
extra-uterine sites, most commonly implanted over visceral and peritoneal surfaces within 
the female pelvis (1). Though endometriosis has been described for the first time in 1690 by 
the German physician, Daniel Shroen, researchers remain still unsure as to the definitive 
cause of this disease (2). The most widely accepted theory for the pathogenesis of 
endometriosis (retrograde menstruation/transplantation), proposed in the 1927 by Sampson 
(3). Although a great deal has been learned about endometriosis since Sampson’s land mark 
studies, there is still a lot about it that is unclear and controversial. It remains an enigmatic 
disorder in that the cause, the natural history, and the precise mechanisms of its 
presentation are not known (4).  
Endometriosis is most commonly found on the pelvic peritoneum but may also be found on 
the ovaries, rectovaginal septum, ureter, and rarely in the bladder, pericardium, and pleura. 
More rarely, colon, small intestine, appendix, umbilical scar and even sites not closely 
contiguous to the pelvis (e.g., lung and brain tissue) may also be involved (5). It is a leading 
cause of disability in women of reproductive age, responsible for dysmenorrhea, pelvic pain 
and subfertility. The most common symptoms for women who have endometriosis are 
pelvic pain and infertility; both adversely affecting the quality of life. The pregnancy rate in 
women with endometriosis is about half of women with tubal factor infertility and is 
negatively correlated with the severity of disease. The cause of reproductive failure may be 
due to poor oocyte development, implantation or embryogenesis. In addition to infertility, a 
strong cause–effect relationship between endometriosis and pelvic pain is commonly 
observed (6, 7). Dysmenorrhoea is associated with cyclic recurrent microbleeding within 
various entities of ectopic endometriotic implants and consequent inflammation. 
Endometriosis-related adhesions and compression or infiltration of nerves in the 
subperitoneal pelvic space by ectopic lesions also cause painful symptoms (8, 9). 
In the last few years, there is a growing interest in endometriosis, because of the large 
number of women it affects (about 3–10% of the female population in the reproductive age, 
and up to 40–80% of women complaining of pelvic pain) and the significant morbidity 
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associated with this disease, mainly with regard to the possible consequences on 
reproductive function and on the risk of developing gynecologic tumors, such as ovarian 
cancer (10-12). The prevalence in women without symptoms is 2-50%, depending on the 
diagnostic criteria used and the populations studied (9). The incidence of endometriosis is 
difficult to quantify, as women with the disease are often asymptomatic, and imaging 
modalities have low sensitivities for diagnosis. The primary method of diagnosis is 
laparoscopy, with or without biopsy for histologic diagnosis (13, 14). Using this standard, 
investigators have reported the annual incidence of surgically diagnosed endometriosis to 
be 1.6 cases per 1,000 women aged between 15 and 49 years. The incidence is 40-60% in 
women with dysmenorrhoea and 20-30% in women with subfertility. The severity of 
symptoms and the probability of diagnosis increase with age. The most common age of 
diagnosis is reported as around 40, although this figure came from a study in a cohort of 
women attending a family planning clinic (15). 
The clinical picture of endometriosis is widely heterogeneous. A correct diagnostic work-up 
of these patients can sometimes be very difficult, since there are a number of gynecological, 
intestinal and systemic diseases mimicking endometriosis, as well as other conditions that 
could be associated with or area consequence of this disorder. Therefore, multidisciplinary 
care should been courage to ensure correct evaluation and improve the management of 
these patients (16). 
2. Prevalence 
Although endometriosis was originally felt to be a disease only seen in women who had 
undergone a minimum of 5 years of ovulatory menstrual cycles, it is now well-documented 
that endometriosis can be seen as early as the premenarchal age group, in girls who have 
initiated thelarche (63). Prevalence is estimated to be 6–10% in the general female population 
and 35–50% of the patients experience pain and/or infertility. The prevalence in women 
without symptoms is 2-50%, depending on the diagnostic criteria used and the populations 
studied (9). The true incidence of endometriosis in adolescents is difficult to quantify and 
estimates vary among different studies. The incidence of endometriosis is difficult to 
quantify, as women with the disease are often asymptomatic, and imaging modalities have 
low sensitivities for diagnosis. Using this standard, investigators have reported the annual 
incidence of surgically diagnosed endometriosis to be 1.6 cases per 1,000 women aged 
between 15 and 49 years (64). The incidence is 40-60% in women with dysmenorrhoea and 
20-30% in women with subfertility. According to the Endometriosis Association, 66% of 
adult women with endometriosis report the onset of pelvic symptoms before age 20, and 
those who seek care for symptoms as a teen see on average 4 or more physicians before 
receiving a diagnosis (15). 
3. Classification 
The primary method of diagnosis is visualization of endometriotic lesions by laparoscopy, 
with or without histologic confirmation. Since the extent of endometriosis can vary widely 
between individuals, attempts have been made to develop a standardized classification to 
objectively assess the extent of endometriosis. Sampson, Acosta et al., and many other 
investigators developed staging systems that have all been criticized for multiple reasons, 
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including their inability to predict clinical outcomes, especially pregnancy rates (PRs) in 
infertile patients. In 1979, the American Fertility Society (AFS) (now the American Society 
for Reproductive Medicine, or ASRM) first proposed a classification system. This was 
extensively evaluated, modified in 1985, and is still used today. Despite these revisions the 
currently used revised AFS system has serious limitations, including not effectively 
predicting the outcome of treatment.  
 
The endometriosis fertility index (EFI) is a simple, robust, and validated clinical tool that 
predicts PRs for patients after surgical staging of endometriosis (see figure below). The EFI 
score ranges from 0–10, with 0 representing the poorest prognosis and 10 the best prognosis. 
Half of the points come from the historical factors and half from the surgical factors. Uterine 
abnormality was not included in the score. The EFI is very useful in developing treatment 
plans in infertile patients with endometriosis. The EFI is useful only for infertility patients 
who have had surgical staging of their disease. It is not intended to predict any aspect of 
endometriosis-associated pain. It is required that the male and female gametes are 
sufficiently functional to enable attempts at non-IVF conception. One factor found to predict 
pregnancy that is not included in the EFI is uterine abnormality. Sensitivity analysis showed 
that even with substantial variation in the assignment of functional scores the EFI varies 
very little (65). 
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4. Anatomic sites 
Endometriosis may develop anywhere within the pelvis and on other extrapelvic peritoneal 
surfaces. Although the condition is usually limited to the ovaries, uterosacral ligaments, 
and Douglas’ pouch, it has been reported in almost every organ of the body. Extra-pelvic 
endometriosis refers to endometrial implants found elsewhere in the body, including the 
skin, central nervous system, gastrointestinal tract, urinary tract, lungs, and heart. 
Macroscopically, three forms of endometriosis are described: superficial peritoneal (or 
ovarian) endometriosis, endometriotic cyst of the ovary or ovarian endometrioma, and deep 
infiltrating endometriosis (DIE).(4) 
The most commonly affected sites are the pelvic organs and peritoneum, although other 
parts of the body such as the lungs are occasionally affected. The extent of the disease varies 
from a few, small lesions on otherwise normal pelvic organs to large, ovarian endometriotic 
cysts endometriomas).  
There can be extensive fibrosis in structures such as the uterosacral ligaments and adhesion 
formation causing marked distortion of pelvic anatomy. Disease severity is assessed by 
simply describing the findings at surgery or quantitatively, using a classification system 
such as the one developed by the American Society for Reproductive Medicine (ASRM) 
(1997). There is no correlation between such systems and the type or severity of pain 
symptoms (66).  
Endometriosis typically appears as superficial "powder burn" or "gunshot" lesions on the 
ovaries,serosal surfaces and peritoneum-black, dark-brown, or bluish-puckered lesions, 
nodules or small cysts containing old haemorrhage surrounded by a variable extent of 
fibrosis. Atypical or "subtle" lesions are also common, including red implants (petechial, 
vesicular, polypoid, hemorrhagic, red flamelike) and serous or clear vesicles. Other 
appearances include white plaques or scarring and yellow-brown peritoneal discoloration of 
the peritoneum (66, 67).  
Endometriomas usually contain thick fluid like tar; such cysts are often densely adherent to 
the peritoneum of the ovarian fossa and the surrounding fibrosis may involve the tubes and 
bowel. Deeply infiltrating endometriotic nodules extend more than 5mm beneath the 
peritoneum and may involve the utero-sacral ligaments, vagina, bowel, bladder or ureters. 
The depth of infiltration is related to the type and severity of symptoms (4). 
5. Pathophysiology 
5.1 Etiology  
Despite extensive research, its pathogenesis still remains elusive and the disorder is 
considered to be ‘enigmatic’. Endometriosis is a multi-factorial disease with multi-faceted 
features. The theories that have withstood the test of time and remain in vogue include 
retrograde menstruation, coelomic metaplasia, and endometrial stem cells. All the 
theories on its pathogenesis must be taken complementary to one another and by no way 
are mutually exclusive. The most widely accepted theory is the implantation of viable 
endometrial tissue onto peritoneal visceral structures from retrograde menstrual flow into 
the pelvic cavity (17). However, the origin is multifactorial, also having hormone, 
immune, and genetic components. The relationship of endometriosis to estrogen is well-
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established. Two thirds of women with a diagnosis of endometriosis report having a 
family member with endometriosis. A large percentage of women with endometriosis 
have other co-morbidities such as fibromyalgia, chronic fatigue syndrome, 
hypothyroidism, allergies, asthma, and auto-immune disorders. The associated risk 
factors are directly related to low body mass index (BMI), and family history and are 
inversely related to exercise (18). 
5.2 Retrograde menstruation 
The earliest and most widely accepted theory relates to retrograde menstruation through the 
fallopian tubes with subsequent dissemination of endometrial tissue within the peritoneal 
cavity. Sampson’s theory of endometrial implantation, offered in the 1927, proposes that 
retrograde menstruation through the fallopian tubes was responsible for endometriotic 
lesions. Three prerequisites are necessary for Sampson’s theory: (1) retrograde menstruation, 
(2) viability of menstrual endometrial cells, and (3) implantation of endometrial cells onto 
the peritoneal/ovarian surfaces (3). Since the introduction of his theory, retrograde 
menstruation has been confirmed at laparoscopy, and it appears to occur in the vast 
majority of women. Keettel and Stein in the 1950s demonstrated the viability of shed 
menstrual endometrial cells by invitro culture of menstrual endometrium (19). The viability 
of retrograde menstrual endometrium has been shown by Mungyer et al by culturing 
endometrial glands and stroma collected from peritoneal lavage (20). In addition to these 
invitro studies, Ridley and Edwards injected menstrual blood into the skin of women 
scheduled for a laparotomy in the next 3 to 6 months. On excision of this tissue, several 
women had endometriotic lesions at the injection site. Further circumstantial evidence 
supporting Sampson’s theory is the increased risk of endometriosis in women with 
Mullerian anomalies and other outflow tract obstructions (21).  
Refluxed endometrial fragments adhere to and invade the peritoneal mesothelium and 
develop a blood supply, which leads to continued implant survival and growth. However, 
this theory fails to explain the presence of endometriosis in such remote areas outside the 
peritoneal cavity, as the lungs, skin, lymph nodes, and breasts. Moreover, the presence of 
the disease in early puberty and exceptionally also in newborns further contrasts the 
validity of the theory (22). 
5.3 Coelomic metaplasia 
The coelomic metaplasia theory claims that formation of endometriomas in the ovary or 
recto-vaginal endometriosis is caused by metaplasia of the coelomic epithelium, perhaps 
induced by environmental factors (23). Because the ovary and the progenitor of the 
endometrium, the müllerian ducts, are both derived from coelomic epithelium, metaplasia 
may explain the development of ovarian endometriosis. In addition, the theory has been 
extended to include the peritoneum because of the proliferative and differentiation potential 
of the peritoneal mesothelium. 
This theory would explain why most women have some degree of retrograde menstruation 
but only a little percentage has endometriosis and the presence of the disease in absence of 
menses. However, the absence of endometriosis in other tissues derived from coelomic 
epithelium argues against this theory (22). 
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5.4 Induction theory 
The theory of endometrial stem cells or transient amplifying progenitor cells claims that 
circulating stem cells originating from bone marrow or from basal layer of endometrium 
could differentiate into endometriotic tissue at different anatomical sites (24). In vitro 
studies have demonstrated the potential for ovarian surface epithelium, in response to 
estrogens, to undergo transformation to form endometriotic lesions. Although many 
putative factors have been identified, their propensity to cause endometriosis in some 
women but not in others demonstrates the still unidentified etiology of this disease (25). 
5.5 Lymphatic or vascular spread 
Evidence also supports the concept of endometriosis originating from aberrant lymphatic or 
vascular spread of endometrial tissue. Findings of endometriosis in unusual locations, such 
as the perineum or groin, bolster this theory. The lymphatic and hematogenous spread of 
endometrial cells can explain the presence of endometriosis in the pelvis or elsewhere. 
However, in the last few years, strong evidence indicates the possible role of immunologic 
factors and the lack of adequate immune surveillance in the pathogenesis of endometriosis 
(26, 27). 
5.6 Hormonal effect 
Endometriosis is an estrogen-dependent disorder. Aberrant production of estrogen by 
endometriotic stromal cells is indispensable for the development and maintenance of 
endometriosis especially during the period of menstruation when no ovarian estrogen is 
available. This notion was supported by identification in endometriotic stromal cells of the 
presence of all proteins/enzymes required for denovo synthesis of estrogen:steroidogenic 
acute regulatory protein (StAR), P450 side-chain cleavage enzyme (P450scc), 3b-hydroxy 
steroid dehydrogenase (3b-HSD), 17 a-hydroxylase 17,20 lyase, P450 aromatase and 17b-
HSD type1. Among these enzymes, StAR and aromatase control the first and last committed 
steps in the biosynthesis of estrogen. StAR transports cholesterol across the mitochondrial 
membrane to the inner mitochondrial leaflet, where the first enzymatic reaction occurs. 
Aromatase catalyses the conversion of androstenedione to estrone. Estrone is further 
converted to 17b-estradiol (normally referred to a sestrogen) by 17b-HSD type1, whereas 
17b-HSD type2 reverses this process. In disease-free uterine endometrium, no StAR or 
aromatase are detected but there are increased StAR and aromatase levels in extra-ovarian 
endometriotic implants and endometriomas. In addition, the absence of 17b-HSD type2 in 
pelvic endometriotic implants further favors an increase in the local concentration of 
estrogen (28-30). 
5.7 Steroid receptor genetics 
Endometriosis is an estrogen-dependent disease. The action of steroids such as estrogen, 
progesterone and androgen are mediated through their respective receptors (SRs). SRs are 
ligand (hormone)-dependent transcription factors. Upon activation with the specific 
hormone they can interact with hormone response elements in the promoter of target genes. 
Since the action of steroids such as estrogen, progesterone and androgen are mediated 
through their respective receptors - Estrogen Receptors (ER), Progesterone Receptors (PR) 
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and Androgen Receptors (AR) - these receptors must be and have shown to be intimately 
involved in the pathogenesis of endometriosis. ERs, PRs and AR, along with glucocorticoid 
receptor and mineralocorticoid receptor, form the steroid receptors (SRs) family, which is 
one of three members of the nuclear receptor (NR) superfamily of transcription factors. 
Besides the SR family, other members of the NR superfamily, such as vitamin D receptor, 
retinoic acid receptor, and peroxisome proliferator-activated receptor may also be involved 
in endometriosis (31). 
5.8 Immunologic factors 
There is ample evidence indicating that alterations in both cell-mediated and humoral 
immunity contribute to the pathogenesis of endometriosis. Increased number and activation 
of peritoneal macrophages, decreased T cell and natural killer (NK) cell cytotoxicities are the 
alterations in cellular immunity, yielding diminished removal of ectopic endometrial cells 
from the peritoneal cavity. In addition, increased levels of several proinflammatory 
cytokines and growth factors produced by immune and endometrial cells are likely to be 
involved in facilitating implantation and growth of ectopic endometrial cells by promoting 
proliferation, inflammation and angiogenesis (32). 
There is evidence that TNF-α promotes the adherence of stromal cells to the mesothelium and 
stimulates proliferation of endometriosis stromal cells. Both of these may be important 
mechanisms in the pathogenesis of endometriosis, and it has been suggested that TNF-α is one 
of the essential factors for the pathogenesis and maintenance of endometriosis. Concentrations 
of TNF-α in peritoneal fluid are higher in women with endometriosis than in patients with 
normal pelvic anatomy and peritoneal fluid TNF-α concentrations correlate with the stage of 
endometriosis. Serum TNF-α levels also are significantly increased in patients with 
endometriosis, especially in early stages of the disease. Also, TNF stimulates the expression of 
prostaglandin synthase-2, which in turn increases the production of prostaglandins E2 and 
F2a, an indirect mechanism by which TNF may cause inflammatory pain (33-37). 
Endometriotic implants contain both estrogen and progesterone receptors and respond to 
changes of hormonal levels with bleeding or production and release of inflammatory 
mediators, especially prostaglandins E2 and F. For a long time, it has been thought that 
prostaglandins are involved in endometriosis-related severe dysmenorrhea, and probably 
dyspareunia and nonmenstrual pelvic pain. Some of the data suggest that endometriotic 
lesions actually may produce greater amounts of prostaglandins than does eutopic 
endometrium. In fact, prostaglandins in endometriosis were produced mainly by Cox-2 (38-
40). Matsuzaki et al. found higher levels of Cox-2 in the epithelium and the stroma of 
endometriosis than in normal endometrium from controls without endometriosis. They also 
found higher levels of Cox-2 in the stroma of eutopic endometrium of women with 
endometriosis than in the stroma of women without endometriosis (41). Ota et al. have 
published similar results, showing higher levels of Cox-2 in endometriosis than in 
endometrium from controls. These data support the conclusion that Cox-2 is induced by 
endometriosis and leads to higher levels of prostaglandins (42). 
5.9 Clinical association between endometriosis and autoimmune diseases 
Clinical conditions associated with endometriosis by patients, providers, and researchers 
alike have included headaches, arthralgias and myalgias, allergies, eczema, hypothyroidism, 
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fibromyalgia, chronic fatigue syndrome, and susceptibility to vaginal candidiasis. These 
often ill-defined entities carry an allure of mystery, paralleling many nonspecific symptoms 
encountered by patients with known autoimmune disease. Because of this parallelism, and 
with no alternative explanation for a patient’s extraperitoneal symptoms, patients and 
health care providers may suspect an immunopathologic mechanism. The potential link 
between autoimmune disease and endometriosis has been studied from a number of 
perspectives. Some investigators have reported common clinical elements among patients 
with endometriosis and patients with various autoimmune processes, whereas others have 
reported interesting serologic parallels (43-46). 
6. Risk factors 
6.1 Genetic factors 
Endometriosis regarded as a genetic disease due, apparently, to its reported familial 
aggregation. Yet even the reported familial aggregation, when examined closely, may be 
debatable and there has been little progress regarding the identification of genetic variants 
that predispose women to endometriosis. First degree relatives of patients with 
endometriosis have a 6.9% incidence of endometriosis in comparison with a 1% risk in 
controls (47). 
There is a prevailing view that endometriosis is a polygenic disease and, as such, genetic 
polymorphisms that predispose women to endometriosis can be identified through linkage 
or association studies. In the last decade, numerous large-scale gene expression profiling 
studies have demonstrated, unequivocally, that many genes such as oncogenic K-ras are 
deregulated in endometriosis. Yet despite many publications, seemingly little headway has 
been made in elucidating the specific genetic factors that have a major impact on the risk of 
developing endometriosis. Few, if any, positive findings from genetic association studies 
have been replicated, and those who tried to replicate previously reported positive findings 
often end up with negative results. Not surprisingly, three meta-analyses on association of 
endometriosis and some genetic polymorphisms coding for dioxin detoxification enzymes, 
sex steroid biosynthesis and their receptors found no evidence of association even though 
meta-analyses known to have upward biases in risk estimates, especially the ‘winner’s 
curse’ of first reports (48-49). 
6.2 Environmental factors and dioxin 
Environmental factors, such as dioxin, might interact with multiple genetic susceptibility 
loci to produce the phenotype of endometriosis. Most of these environmental contaminants 
exhibiting estrogenic effects will lead to endocrine disruption through various 
environmental media such as food and water. Dietary intake of dioxin-like compounds with 
biological activity will increase the body burden (the total amount of these chemicals that 
are present in the human body at a given point in time), which might contribute to the 
pathogenesis of endometriosis. In addition, these chemicals can pass through the placenta to 
affect fetal environment. In a prospective cohort study, the rate of laparoscopically 
confirmed endometriosis was 80% greater among women exposed in utero to 
diethylstilbestrol (a synthetic estrogen originally prescribed in pregnancy to prevent 
miscarriage) after 10 years of follow-up. However, the relationship between endocrine 
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disrupting chemicals and endometriosis remains controversial because of lack of studies 
with sufficient statistical power (50-54). 
Several excellent reviews have been published characterizing dioxins. Chemically, dioxin, an 
abbreviation of 2, 3, 7, 8-tetrachloro-dibenzo-p-dioxin, or TCDD, is a polycyclicaromatic agent 
with chloral substituent.  Dioxin is a lipophilic material that could accumulate in tissues with a 
high fat content. There is insufficient evidence at this moment in support of the hypothesis that 
dioxin exposure may lead to increased risk of developing endometriosis in women. Dioxins 
may act similarly to estrogen in estrogen-target tissues such as endometrium (eutopic or 
ectopic), promoting proliferation. However, it should be noted that in the presence of Aryl 
hydrocarbon Receptor (AhR) agonists, the function of liganded ER is attenuated. Since the 
local estrogen production is increased in endometriosis due to aberrant regulation of 
aromatase and of type 2 17 b-hydroxy steroid dehydrogenase, it is unclear what the net effect 
of AhR agonists such as dioxins is on ectopic endometrium (55-57). 
6.3 Anatomic defects 
Reproductive outflow tract obstruction can predispose to development of endometriosis, 
likely through exacerbation of retrograde menstruation. Accordingly, endometriosis has 
been identified in women with noncommunicating uterine horn, imperforate hymen, and 
transverse vaginal septum. Because of this association, diagnostic laparoscopy to identify 
and treat endometriosis is suggested at the time of corrective surgery for many of these 
anomalies. Repair of such anatomic defects is thought to decrease the risk of developing 
endometriosis (58, 59). 
A number of Mullerian anomalies, most importantly those associated without flow tract 
obstruction, are associated with endometriosis. In a series by Schifrin et al. 15 patients (40%) 
younger than 20 years of age with endometriosis had a genital tract anomaly (60). This is 
opposed to findings by Goldstein et al who noted congenital anomalies in only 11% of 74 
teenagers with endometriosis (61). The clinical course of endometriosis associated with 
reproductive tract anomalies is quite different from that in the adult. Sanfilippo et al 
described a series of patients with extensive endometriosis in association with outflow tract 
obstruction (62). Once correction of the outflow tract occurred, there was virtually 100% 
reversal of intra-abdominal endometriosis on follow-up laparoscopy. It is thought that the 
pathophysiology of the disease process is different in the adult as compared with 
adolescents with an outflow tract obstruction. Interestingly, the fact that many adolescents 
without flow tract obstruction show significant endometriosis at the time of laparoscopy 
does support the theory of retrograde menstruation as an etiology for development of 
endometriosis. However, given that endometriosis resolves without further treatment after 
correction of the outflow tract abnormality suggests that retrograde menstruation, in and of 
itself, is not sufficient to induce a state of progressive endometriosis. Other factors besides 
retrograde menstruation, such as immune system defects, may be fundamental to creating 
an environment for induction of progressive endometriosis (63). 
7. Patient symptoms 
Although women with endometriosis may be asymptomatic, symptoms are common and 
typically include chronic pelvic pain and infertility. As previously stated, the current ASRM 
www.intechopen.com
 
Endometriosis - Basic Concepts and Current Research Trends 12
classification of endometriosis, which describes the extent of disease bulk, poorly predicts 
symptoms. Thus clinically, women with extensive disease (stage IV) may note few 
complaints, whereas those with minimal disease (stage I) may have significant pain or 
subfertility or both (68, 69). 
The following symptoms can be caused by endometriosis based on clinical and patient 
experience:   
• Severe dysmenorrhoea; 
• Deep dyspareunia; 
• Chronic pelvic pain; 
• Ovulation pain; 
• Cyclical or perimenstrual symptoms (e.g. bowel or bladder associated) with or without 
abnormal bleeding; 
• Infertility; 
• Chronic fatigue.   
However, the predictive value of any one symptom or set of symptoms remains uncertain as 
each of these symptoms can have other causes. A large group of women with endometriosis 
is completely asymptomatic. In these women endometriosis remains undiagnosed or is 
diagnosed atlaparoscopy for another indication. A subset of women with more advanced 
disease, ovarian or deep invasive rectovaginal endometriosis, is asymptomatic as well. This 
makes the development of guidelines for the diagnosis and the therapy rather cumbersome. 
Endometriosis should be suspected in women with dysmenorrhoea, deep dyspareunia, 
acyclic chronic pelvic pain and/or subfertility.  
8. Physical examination 
Physical examination of the pelvis is useful for the diagnosis of deep infiltrating lesions or 
endometriotic cysts. The examination may be normal. It is more reliable when carried out 
during the menstrual period. Examination of the retrocervical area using the speculum, by 
vaginal and (possibly) rectal examination, is recommended. Examination of the vagina and 
cervix by speculum examination often reveals no signs of endometriosis. Occasionally, 
bluish or red powder-burn lesions may be seen on the cervix or the posterior fornix of the 
vagina. Pelvic organ palpation often reveals anatomic abnormalities suggestive of 
endometriosis. Uterosacral ligament nodularity and tenderness may reflect active disease or 
scarring along the ligament. In addition, an enlarged cystic adnexal mass may represent an 
ovarian endometrioma, which may be mobile or adherent to other pelvic structures (15, 63). 
9. Differential diagnosis 
The symptoms of endometriosis are nonspecific and may mimic many disease processes. 
Because endometriosis is a surgical diagnosis, several other diagnoses may be considered 
prior to surgical exploration. Since there is such an extremely variable presentation, an 
accurate differential diagnosis should always be performed in patients suspected of 
endometriosis. First of all, other gynecological disorders, such as ovarian and tubal diseases, 
pelvic inflammatory disease and ectopic pregnancy, should be excluded (16). Then a series 
of gut disorders should be considered; among these conditions, irritable bowel syndrome 
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(IBS) is worthy of particular attention (70). Crohn’s disease should also be considered in the 
differential diagnosis of endometriosis, since this condition shows several similarities 
regarding both the locations and the anatomo-pathologic pattern (71). Although rare, 
familial Mediterranean fever (FMF) should be considered in the differential diagnosis of 
endometriosis (72). Rarely the presence of parasitic infestations has been reported in women 
with symptoms suggestive of endometriosis (73). 
10. Laboratory testing 
To exclude other causes of pelvic pain, laboratory investigations are often undertaken. 
Initially, a complete blood count (CBC), urinalysis and urine cultures, vaginal cultures, and 
cervical swabs may be obtained to exclude infections or sexually transmitted infections that 
may cause pelvic inflammatory disease (63). 
Although concentrations of the cancer antigen CA125 are slightly raised in some women 
with endometriosis, the test neither excludes nor diagnoses endometriosis and is not 
considered useful in establishing the diagnosis. The threshold for surgery is unlikely to be 
influenced by the CA125 concentration and the guidelines from the Royal College of 
Obstetricians and Gynecologists described CA125 as having only limited value as either a 
screening or a diagnostic test (15). 
11. Imaging and endometriosis 
Endometriomas are uncommon in the adolescent population, and information regarding the 
adnexa can be obtained noninvasively with a pelvic ultrasound. Ultrasound as the primary 
imaging investigation can aid in its diagnosis. Transvaginal ultrasound (TVUS) with color 
flow Doppler can detect endometriomas with a high degree of accuracy. Ultrasound is 
limited in its ability to detect small peritoneal implants and adhesions (74).  
MRI is an excellent imaging modality for the evaluation of patients with deep pelvic 
endometriosis, showing high accuracy in the diagnosis and prediction of disease extent. The 
MRI diagnosis of deep pelvic endometriosis is based on the conjoint presence of signal 
intensity and morphologic abnormalities in the anterior and posterior compartments of the 
pelvis and the presence of surrounding fibrosis. The use of endovaginal and rectal contrast 
is useful to better delineate the anatomy and map out the extent of disease. Atypical 
locations of deep pelvic and extrapelvic endometriosis have been presented and grouped 
under the term anterior endometriosis. An accurate diagnosis therefore resides in clinical 
awareness and systematic review via MRI. A key finding of malignant transformation is the 
presence of enhancing nodules in the endometrial cyst on T1-weighted images (74, 75). 
12. Laparoscopic findings 
Laparoscopy is the gold standard for the diagnosis and staging of endometriosis and allows 
for curative surgical resection at the same time. Patients found to have endometriosis at the 
time of laparoscopy should either be treated through surgical ablation, resection, or laser 
treatment. In addition, biopsy is recommended, as lesions of endometriosis in adolescents 
often take on a different appearance as compared with the typical powder-burn lesions seen 
in adults. Interestingly, clear or red endometriotic lesions are much more commonly seen in 
the adolescent population (76). 
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13. Histological confirmation 
Histologic confirmation is essential in the diagnosis of endometriosis. The utility of 
peritoneal wash cytology for diagnosis of endometriosis has been reported. In most cases, 
only hemosiderin-laden macrophages are identified. The presence of endometrial cells is 
more specific but less sensitive than hemosiderin-laden macrophages for the diagnosis of 
endometriosis. The endometrial cells have been reported in 25%–52% of peritoneal washes 
done in endometriosis. However, recognition of endometrial cells as well as hemosiderin-
laden macrophages is essential for diagnosis on morphological basis alone. Histologic 
examination of the tissue confirmed for endometriosis by the presence of both endometrioid 
glands and stroma (15).  
14. Treatment 
Treatment must be individualized, and the effect of the kind of treatment on quality of life 
must be considered. There is not any confidence that a uniform therapeutic way be 
enough and successful, however in the most of the patients there is not a curative 
treatment. The choice of treatment is based on various factors such as size, location and 
extent of the disease, type and severity of the symptomatology, wish for pregnancy, and 
age of the patient. (77) Planning for the treatment is based on two important symptoms: 
pain and infertility. All the therapeutic ways divide to two main surgical and medical 
treatments. 
14.1 Medical treatment 
1. Selective progestron receptor modulators, progestogens and  anti progestins 
(Androgens) 
2. Gn-RH agents 
3. COC ( Combined Oral Contraceptives) 
4. Aromatase inhibitor & NSAIDs and cox2- inhibitors 
5. Chinese Medications 
6. Angiogenesis  inhibitor 
7. Gene Therapy 
8. Modulation of Cytokines , inhibition of Matrix Metalloproteinase 
I.     Selective progestron receptor modulators,  progestogens and  anti progestins 
a. Progestogens 
1. Medroxyprogestrone acetate / 30 mg /po /daily 
2. Megestrol acetate / 40 mg / po / daily  
3. Lynoestrenol / 10 mg / po / daily 
4. Dydrogestrone / 20-30 mg / daily 
The role of the LNG IUS ( Levonorgestrel  intra uterin system ) in management of this 
common and troublesome disorder has been evaluated by multiple studies.( 78-80) 
A pilot study examined the role of LNG IUS as a postoperative adjunct to surgical ablation 
for endometriosis. When compared with expectant management, the LNG IUS recipients 
had a reduced rate of recurrence of pelvic pain (2/20 compared with 9/20) and an increased 
rate of satisfaction (15/20 compared with 10/20). (81) The LNG IUS offers several 
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advantages for control of pelvic pain associated with endometriosis, including effective 
contraception, minimal systemic effects, and up to 5 years of benefit, as compared with 6 
months, typical of GnRHa treatment. 
Dienogest (DNG), a progestin of 19‑nortestosterone derivative, has good oral bioavailability 
and is highly selective for progesterone receptors. Owing to its antiovulatory, 
antiproliferative activities in endometrial cells, and its inhibitory effects on the secretion of 
cytokines, DNG is expected to be an effective treatment for endometriosis. Progesterone 
receptor-binding affinity is higher for DNG than for progesterone. 
• DNG has moderate affinity to the progesterone receptor. DNG shows low binding to 
the androgen receptor and almost negligible binding to the estrogen receptor, 
glucocorticoid receptor and mineralcorticoid receptor. 
• DNG has strong oral progestational activity but antiandrogenic activity. 
• An oral DNG dose of 1 mg/day is required for inhibition of ovulation in cyclic women. 
• DNG has an inhibitory effect on growth and cytokine production of endometriotic cells. 
• DNG is as effective as triptorelin (gonadotropin-releasing hormone agonist) for 
consolidation therapy after surgery for the treatment of endometriosis. 
• DNG is as effective as intranasal buserelin acetate for the relief of pain symptoms 
associated with endometriosis.(82) 
Treatment with a GnRH-a followed by long-term dienogest therapy maintains the relief of 
endometriosis-associated pelvic pain achieved with GnRH-a therapy for at least 12months. 
This regimen reduces the amount of irregular uterine bleeding that often occurs during the 
early phase of dienogest therapy.(83) 
Complex mechanisms involving promoter regulation may be responsible for the observed 
aberrations in (Estradiol Receptor a, b) ERa, ERb, and PR (progesterone Receptor) 
expression in endometriosis. The stromal cell component of endometriotic tissue may be the 
primary site of these abnormalities. In endometriotic stromal cells, ERb promoter is 
pathologically hypomethylated and therefore hyperactive, leading to very high ERb levels. 
ERb suppresses ERa expression and results in strikingly high ERb-to-ERa ratios in 
endometriotic cells. 
It is possible that this consequence of PR-B deficiency is only the tip of the iceberg with 
regard to pathogenesis of endometriosis, and that numerous other molecular aberrations 
may also contribute to the development of resistance to hormone treatments in women with 
endometriosis. Selective ERb ligands that target high levels of ERb in endometriotic tissue 
may be clinically beneficial via disrupting this mechanism.(84) PR deficiency is likely 
responsible for increased levels of E2 in endometriosis because progesterone fails to induce 
the E2-metabolizing enzyme HSD17B2 in endometriotic tissue. Some conclusion resonates 
with gene expression microarray studies performed on eutopic endometrium of women 
with endometriosis compared with that from disease-free women.(85, 86) These studies on 
eutopic endometrium identified distinct molecular defects that are consistent with the 
progesterone resistance hypothesis. 
ER b agonists act as immunomodulators, enhancing the immunologic response to the 
explants; a second possible explanation lies an antiangiogenic effect because ER b are 
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present in endothelial cells of endometrial vasculature. Finally, it is possible that b receptor 
acts intracellularly as an ERa inhibitor, by dimerizing with the ERa molecules to form a 
faulty product (87). 
b. Antiprogestins: 
- Danazol  400-800 mg/day 
- Gestrinone 1.25-2.5 Twice /week 
The first medication approved for the treatment of endometriosis in the United States was 
the androgen danazol. The predominant mechanism of action appears to be suppression 
of midcycle luteinizing hormone (LH) surge, creating a chronic anovulatory state as a 
result, danazol creates a hypoestrogenic, hyperandrogenic state, inducing endometrial 
atrophy in endometriotic implants. The recommended dosage of danazol is 600 to 800 mg 
daily. Unfortunately, significant androgenic side effects develop at this dosage and 
include acne, hot flashes, hirsutism, adverse serum lipid profiles, voice deepening 
(possibly irreversible), elevation of liver enzymes, and mood changes. Moreover, due to 
possible teratogenicity, this medication should be taken in conjunction with effective 
contraception. Because of this adverse side-effect profile, danazol is prescribed less 
frequently, and when administered, its duration should be limited. Gestrinone 
(ethylnorgestrienone; R2323) is an antiprogestational agent prescribed in Europe for the 
treatment of endometriosis. Gestrinone equals the effectiveness of danazol and of GnRH 
agonists for relief of endometriosis-related pain. Mifepristone is a PA (Progestron 
Antagunist) currently approved only for use in medication abortion and, in some 
countries, as an emergency contraceptive, but 3 small trials have demonstrated a 
reduction in endometriosis symptoms with Mifepristone therapy.(88 ,89) 
II.     Gn-RH agents 
- Lueprolide  500mg/DAY  SC or 3.75 mg /month IM 
- Gosereline  3.6 mg /month SC 
- Buserelin IN 300 /day 
- Nafarelin IN 200/day 
- Triptorelin 3.75 mg /month IM 
Treatment with GnRHa for 3 months is as effective as the 6-months treatment as far as pain 
is concerned, and when combined with estro-progestational agents (‘add-back therapy’) up 
to a maximum of 2 years, is effective for pain and safe in terms of protecting bone 
density.(77) 
Like GnRH agonists, the GnRH antagonists share some homology with the native GnRH 
molecule. These drugs act by blocking the GnRH receptor directly and preventing it from 
activating. This result in a downregulation of the pituitary gland, a reduction of 
gonadotropin secretion, and a suppression of ovarian steroid production Unlike GnRH 
agonists, however, these drugs do not cause an initial stimulation of gonadotropin and 
ovarian hormone secretion. At the molecular level, GnRH antagonists interrupt the basic 
activation process of the GnRH receptor, blocking the receptor dimerization synthesis and 
secretion of luteinizing hormone (LH) and follicle stimulating hormone (FSH). Given the 
high binding affinity, relative abundance and long half-life of the antagonist, these 
molecules monopolize the GnRH receptors. As a result of the above characteristics, the 
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GnRH antagonists offer the theoretical advantage of working faster and more effectively 
than GnRH agonists, with better patient compliance because of earlier amelioration of 
symptoms (90). 
III.     COC (Combined Oral Contraceptives) 
Hormone therapy obtains a good initial response, is well tolerated by patients, and can be 
discontinued if there are adverse effects. Combined hormone therapy with estrogens and 
progesterone [91] has been used for small lesions, with total or partial remission of the 
symptoms in a high percentage of cases. Medical treatment alone does not lead to the 
definitive cure of deep, severe endometriosis but only induces temporary disappearance of 
active lesions [92] 
These drugs can be used conventionally in a cyclic regimen or may be used continuously, 
without a break for withdrawal menses. The continuous regimen may be preferable for its 
decreased frequency of menses for women who fail to achieve pain relief with cyclic COC 
therapy. To maintain relief from pelvic pain while minimizing hypoestrogenic side effects, 
several regimens are proposed. Oral contraceptives plus dienogest, a novel progestogen, or 
a gonadotropin-releasing hormone agonist with estrogen supplementation (add-back 
therapy) can be used in long-term administration. The relief from pelvic pain achieved with 
a gonadotropin-releasing hormone agonist can be sustained by long-term administration of 
a tapered dose of danazol or medium-to-low doses of oral contraceptives. Local treatment 
with the levonorgestrel-releasing intrauterine system is an option for long-term suppression 
of pelvic pain.(93) For patients with recurrent ovarian endometriosis after conservative 
surgery or conservative surgery plus medical therapy, LNG-IUS and COC (combined oral 
contraceptives)  may be used to control and reduce endometriotic cysts, relieve pain and 
reduce the level of CA125. LNG-IUS has the advantages of a greater convenience and minor 
systemic side effects (94). Long-term OCP therapy can be a reliable adjuvant post-operative 
measure to prevent or reduce frequency/severity of recurrent dysmenorrhoea and 
anatomical relapse of endometriosis. Since both continuous and cyclic OCP administration 
regimens seem to have comparable effects, the choice of regimen can be modulated 
according to patient preferences. The protective effect seems to be related to the duration of 
treatment.(95) 
IV.     Aromatase inhibitor & NSAIDs and cox2- inhibitors 
Large quantities of estrogen can be produced locally within ectopically located 
endometrium via an intracrine mechanism, via the expression of the enzyme aromatase. 
This enzyme, not expressed in normal endometrium, is stimulated by prostaglandin E2 
(PGE2); the resulting estrogen production then stimulates PGE2, further enhancing 
estrogen. An obvious therapeutic target would thus be this aromatase enzyme and 
aromatase inhibitors were tested in the rodent endometriosis model, with good success 
[96]. 
The expression of COX-2 was recently demonstrated in ectopic endometrial cells, showing 
higher concentration with respect to the eutopic endometrium [97]. COX-2 selective 
inhibitor given at the minimal dosage is effective against the pelvic pain symptoms 
(dysmenorrhoea, dispareunia, and chronic pelvic pain) associated to endometriosis [98]. 
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Aromatase inhibitors have similar hypoestrogenic side-effect profiles as GnRH agonists, but 
hold promise in severe, refractory cases of endometriosis. 
Treatment of rats with induced endometriosis using the nonsteroidal aromatase inhibitor 
fadrozole hydrochloride or YMsl l resulted in a dose-dependent volume reduction of 
endometriosis transplants.(99, 100) 
In a pilot study, preliminary data were generated suggesting a potential future use of this 
drug, but randomized controlled trials are needed to confirm these data.(101) The effect of 
medical treatment in terms of pain relief in women with rectovaginal endometriosis appear 
substantial.(102) 
V.     Chinese Medications (CM) 
In recent years, the Chinese medicine treatment of EM has won favorable therapeutic effects 
with few adverse reactions. The CM treatment of EM puts stress on therapy according to 
syndrome differentiation, varying the treatment for different individuals and emphasizing 
different sides in different stages of a menstrual cycle. It is non-traumatic with less adverse 
effect and good long-term effectiveness. It is favorable in combination with various 
approaches like acupuncture and moxibustion, retention enema and Western medical 
treatment, and could be extensively applied in clinical practice to function effectively in 
improving clinical symptoms and physical signs of patients and raising their quality of 
life.(103) Dong, et al treated EM with Guizhi Fuling capsule combined with intervention 
paracentesis implemented under ultrasonographic guidance to achieve good efficacy. The 
patients' cystic fluid was drawn out through puncturing and then the cystic cavity was washed 
repeatedly with 0.5% Lidocaine, then absolute alcohol was injected into the cavity The 
outcome shows that the therapeutic efficacy in the two groups was the same, but adverse 
reaction of Guizhi Fuling Capsule was significantly less than that of Gestrinone.(104) 
Xue treated 41 patients with Mifepristone (25 mg/d, starting from the 1st day of the 
menstruation) combined with Chinese decoction, consisting of chuanxiong, dragon's blood, 
peach kernel, achyranthes root, yanhusuo rhizome, typha, trogopterus dung, red peony 
root, Chinese angelica root, cyperus tuber, red sage root, etc., one dose a day for 6 successive 
months, and the total effective rate obtained was 92.7%, which was better than that of 
Mifepristone or Chinese herbal medicine alone.(105) 
Yu used Xiaoyi Zhitong Decoction combined with Mifepristone to treat 76 patients for 3 
months, which resulted in a total effective rate of 92% and a recurrent rate of 5.3%.(106) 
VI.     Angiogenesis inhibitors 
The most prominently studied among angiogenic factors is the vascular endothelial growth 
factor (VEGF), which is responsible for inducing early vascular growth. In any event, one 
logical therapeutic step would be to attempt inhibition of these new vascular structures as a 
way of deterring the development of endometriosis. The only human study thus far 
conducted with an angiogenesis inhibitor was the treatment of endometriosis associated 
pain with thalidomide; pain relief was noted in these patients [107]. 
VII.     Gene Therapy 
HOX genes, encoding homeodomain transcription factors, are dynamically expressed in 
endometrium, where they are necessary for endometrial growth, differentiation, and 
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implantation. In human endometrium, the expression of HOXA10 and HOXA11 is driven by 
sex steroids, with peak expression occurring at time of implantation in response to rising 
progesterone levels. However, the maximal HOXA10 and HOXA11 expression fails to occur 
in women with endometriosis resistance to progesterone which can explain inhospitable 
implantation environment and medical treatment failures in endometriosis. Alterations in 
progesterone receptor expression and decreased HOX gene expression secondary to 
hypermethylation of its promoter region are the possible mechanisms of the progesterone 
resistance. A gene therapy approach involving the manipulation of HOXA10 expression or 
by using DNA demethylation agents to restore methylation aberrations can potentially have 
a role in the future treatment of endometriosis.(108-110) 
A new study compared women suffering chronic pelvic pain (CPP) secondary to 
endometriosis with women experiencing CPP due to either myofascial abdominal/pelvic 
pain or pelvic adhesions to determine if there are specific psychological variables uniquely 
associated with endometriosis .No differences were obtained across the three groups for any 
of the outcome measures. Effect size computation supported the absence of clinical 
differences across the groups for these measures.  These findings fail to support the presence 
of a unique psychological profile or disproportionate psychological disturbance for women 
with CPP due to endometriosis. These data illustrate the importance of considering control 
groups that include chronic pain when exploring psychological contributions to specific 
chronic pain conditions.(111) 
VIII.     Modulation of Cytokines, lnhibition of Matrix Metalloproteinase 
In rats with experimental endometriosis, recombinant human TNF-α-binding protein can 
reduce 64% of the size of endometriosis-like peritoneal lesions (112). 
In nude mice, suppression of MMPs by progesterone or by a natural inhibitor slows the 
establishment of ectopic lesions by human endometrium. (113) 
14.2 Surgical treatments 
The goal of surgery is to excise all visible endometriotic lesions and associated adhesions-
peritoneal lesions, ovarian cysts, deep rectovaginal endometriosis-and to restore normal 
anatomy. 
Laparoscopy is the gold standard for diagnosis and the primary means of treatment at this 
time. Laparoscopy is used with different goals such as diagnosis, ablation, excision and lysis 
of adhesions. 
 Excisional removal of ovarian endometriomas seems superior to drainage and ablation for 
both improved spontaneous pregnancy rates and improved pain symptoms. Laparoscopic 
treatment of endometriosis carries a long-term substantial relief of symptoms for a 
significant percentage of women. (114) Laser ablation does not appear to be more effective 
than conventional electrosurgical ablation of endometriosis. 
Radical procedures such as oophorectomy or total hysterectomy are indicated only in severe 
situations and can be performed either laparoscopically or by laparotomy. Laparotomy 
should be reserved for patients with advanced-stage disease who cannot undergo a 
laparoscopic procedure and for those in whom fertility conservation is not necessary. 
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In patients with severe endometriosis it has been recommended that surgical treatment be 
preceded by a 3-month course of medical treatment to reduce vascularization and nodular 
size (115). 
Postoperative medical treatment is rarely indicated because it does not work based on 
randomized trials, because it prevents pregnancy, and the highest pregnancy rates occur 
during the first 6 to 12 months after conservative surgery (116, 117). 
Presacral Neurectomy (PSN): 
For some women, transection of presacral nerves lying within the interiliac triangle may 
provide relief of chronic pelvic pain. PSN is used in a limited manner and not recommended 
routinely for management of endometriosis related pain. 
Laparoscopic presacral neurectomy can be offered to treat midline pelvic pain.(114, 118) 
Deep Rectovaginal and Rectosigmoidal Endometriosis: 
Surgical treatment of DIE (Deeply Infiltrating Endometriosis) requires a professional who is 
able to perform surgery in the gynaecological, urological, gastrointestinal and nervous 
structures of the pelvis, as the disease ‘knows no boundaries’. There is no scientific 
validation either that a multispecialty team approach is superior for the treatment of bowel 
endometriosis, which could also make the multisurgeon model ‘experimental’ and therefore 
unethical. (119) 
Preoperative laxatives, starch-free diet, and full bowel preparation are needed to allow 
perioperative bowel suturing, if needed. Ureter stents may be required before excision of 
peritoneal endometriosis surrounding the ureter. A multidisciplinary approach involving 
gynecologic and gastroenterologic surgeons and urologists is desirable. 
Bladder endometriosis is rare .The common clinical manifestations of bladder endometriosis 
include menouria and urethral and pelvic pain syndrome occurring cyclically. Cystoscopy is 
the most useful diagnostic test with confirmation by histologic study. Treatment must be 
individualized according to the patient’s age, desire for future pregnancies, the severity of 
the symptoms, the site affected, and whether other organs are involved. transurethral 
resection-endometrioma  biopsy to confirm the diagnosis and hormone blockade with LH–
RH analogues is the initial treatment most commonly used in recent years, despite an 
estimated recurrence of 25–35% .(120) 
Analogues have been the medical treatment of choice because their introduction, and the 
estrogens, androgens, progestogens, and danazol used in previous years have fallen into 
disuse because they lead to more adverse effects. Analogues induce a postmenopause like 
anovulatory state, a hypogonadotropic hypogonadism with serum estrogen 
concentrations dropping to sterilization levels, which causes the endometrial tissue to 
regress. (121, 122) 
Ureter endometriosis was related with reproductive tract endometriosis. It has insidious 
process resulting in difficulty for early diagnosis. It's important to treat pelvic deep 
infiltrating endometriosis and ovarian endometrioma to prevent ureter from further 
involvement. Post-operative treatment of pelvic endometriosis is the key point of preventing 
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relapse of ureter endometriosis.(123) The laparoscopic approach for ureteral endometriosis 
is very well tolerated and has a reasonable incidence of complications, as well as a low rate 
of recurrence. 
Considering the difficulty of achieving a strictly scientific approach to low disease 
prevalence, the surgeon dealing with ureteral endometriosis must adapt surgery to achieve 
a balance between conservative purposes and the risk of recurrence on the one hand, and a 
radical approach and risk of morbidity on the other. Ureterolysis could be used as the initial 
surgical step for patients with ureteral endometriosis, and may be the only treatment if the 
extension of ureteral involvement is limited in length and there is no residual ureteral 
damage or dilatation. 
For patients displaying extended severe ureteral involvement, stenosis, or moderate or 
severe hydronephrosis with a high risk of having intrinsic ureteral disease, ureterolysis is 
probably insufficient and ureteroneocystostomy likely represents a wiser surgical strategy 
(124). 
Long-term probability of pain recurrence after repeat conservative surgery for recurrent 
endometriosis varies between 20 and 40%. The association of presacral neurectomy to the 
treatment of endometriosis might be effective in reducing midline pain; however, no 
studies have evaluated this procedure among patients with recurrent disease. The 
medium-term outcome of hysterectomy for endometriosis-associated pain is quite 
satisfactory; nevertheless, probability of pain persistence after hysterectomy is 15% and 
risk of pain worsening 3–5%, with a six times higher risk of further surgery in patients 
with ovarian preservation as compared to ovarian removal. The conception rate among 
women undergoing repetitive surgery for recurrent endometriosis associated with 
infertility is 26%, whereas the overall crude pregnancy rate after a primary procedure is 
41%. 
Repeat conservative surgery for pelvic pain associated with recurrent endometriosis has the 
same limitations as primary surgery, with long-term cumulative recurrence rates ranging 
from 20 to 40%. Conversely, only one woman out of four will conceive after repeat 
conservative surgery for infertility, almost half the pregnancy rate after primary surgery and 
with no substantial advantages over IVF. (102) 
Assisted Reproduction and Endometriosis: 
The treatment of endometriosis-related infertility is dependent on the age of the woman, the 
duration of infertility, the stage of endometriosis, the involvement of ovaries, tubes, or both 
in the endometriosis process, previous therapy, associated pain symptoms, and the 
priorities of the patient, taking into account her attitude toward the disease, the cost of 
treatment, her financial means, and the expected results. 
The success of surgery in relieving infertility is probably related to the severity of 
endometriosis. A recent retrospective multicenter analysis (125) reported cumulative 
pregnancy rates of 39%, 31%, 30%, and 25% in patients with endometriosis stages I , II, III, 
and IV, respectively ,l2 months after surgical treatment. 
Endometriosis-associated infertility can be successfully treated with intrauterine 
insemination, but only if it is done in combination with ovarian stimulation (126). 
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However, there is clear evidence that the pregnancy rate in an insemination program is 
lower in women with endometriosis than in women with unexplained infertility. (127, 
128) More recent studies that reported a normal fertilization rate but a reduced 
implantation rate per embryo transferred in women obtaining oocytes from donors with 
endometriosis (129, 130). This reduced implantation rate could be related to increased 
interleukin-6 levels in follicular fluid of women with endometriosis when compared with 
controls (131). 
15. Recurrence 
Endometriosis tends to recur unless definitive surgery is performed. The recurrence rate is 
about 5% to 20% per year, reaching a cumulative rate of 40% after 5 years. Liu and 
coworkers found an approximately 15-percent rate of recurrence at 2 years following initial 
surgery. Pain recurs within 5 years in about one in five patients with pelvic pain treated by 
complete laparoscopic excision of visible endometriotic lesions (132). 
16. References 
[1] Baldi A, Campioni M, Signorile P G. Endometriosis: pathogenesis, diagnosis, therapy 
and association with cancer. Oncology Reports 2008; 19: 843–6. 
[2] Shroen D. Disputatioin auguralis medica de ulceribus uteri. Jena: Krebs; 1690. p. 6–17. 
[3] Sampson J A. Peritoneal endometriosis due to menstrual dissemination of endometrial 
tissue into the peritoneal cavity. American Journal of Obstetric and Gynecology 
1927; 14:422–69. 
[4] Koninckx P R, Meuleman C, Demeyere S, Lesaffre E, Cornillie F J. Suggestive evidence 
that pelvic endometriosis is a progressive disease, where as deeply infiltrating 
endometriosis is associated with pelvic pain. Fertil Steril. 1991; 55:759–765. 
[5] Razzaghi M R, Rahjoo T, Golshan A. Endometriosis with Pure Urinary Symptoms. Urol 
J. 2009; 6:132-4.  
[6] Halis G, Arici A. Endometriosis and inflammation in infertility. Ann NY Acad Sci. 
2004;1034,300-315. 
[7] Wu M H, Shoji Y, Chuang P C, Tsa S J. Endometriosis: disease pathophysiology and the 
role of prostaglandins. Mol med. 2007; 9(2):  
[8] Brosens IA. Endometriosis–a disease because it is characterized by bleeding. Am J Obstet 
Gynecol. 1997; 176,263-267. 
[9] Fauconnier A, Chapron C. Endometriosis and pelvic pain: epidemiological evidence of 
the relationship and implications. Hum Reprod Update. 2005; 11,595-606. 
[10] Cramer D W. Epidemiology of endometriosis in adolescents. In: Wilson EA (ed) 
Endometriosis. Alan Liss, (1987) NewYork pp5–8 
[11] Kuohung W, Jones GL, Vitonis AF etal. Characteristics of patients with endometriosis in 
the United States and the United Kingdom. Fertil Steril. 2002; 78:767–772. 
[12] VanGorp T, Amant F, Neven P, VergoteI, Moerman P. Endometriosis and the 
development of malignant tumors of the pelvis: a review of literature. Best Pract 
Res Clin Obstet Gynaecol. 2004; 18:349–371. 
www.intechopen.com
 
Endometriosis 23 
[13] Kennedy S, Bergqvist A, Chapron C, et al: ESHRE guideline for the diagnosis and 
treatment of endometriosis. Hum Reprod. 2005; 20(10):2698. 
[14] Marchino GL, Gennarelli G, Enria R, et al: Diagnosis of pelvic endometriosis with use of 
macroscopic versus histologic findings. Fertil Steril. 2005; 84:12. 
[15] Farquhar C. Endometriosis. BMJ 2007; 334:249-53 
[16] Montalto M, Santoro L, D'Onofrio F, Gallo A, Campo S, Campo V, Gasbarrini A, 
Gasbarrini G. Endometriosis, need for a multidisciplinary clinical setting: the 
internist's point of view. Intern Emerg Med. 2010; 5(6):463-7. 
[17] Halme J, Hammond MG, Hulka JF, Raj SG, Talbert LM. Retrograde menstruation in 
healthy women and in patients with endometriosis. Obstet Gynecol. 1984; 64:151–
154 
[18] Troyer MR. Differential Diagnosis of Endometriosis in a Young Adult Woman With 
Nonspecific Low Back Pain. Physical Therapy. 2007; 87(6): 801-10 
[19] Keettel WC, Stein RJ. The viability of the cast-off menstrual endometrium. Am J Obstet 
Gynecol. 1951 Feb;61(2):440-2. 
[20] Mungyer G, Willemsen WN, Rolland R, Vemer HM, Ramaekers FC, Jap PH, Poels LG. 
Cell of the mucous membrane of the female genital tract in culture: a comparative 
study with regard to the histogenesis of endometriosis. In Vitro Cell Dev Biol. 1987 
Feb;23(2):111-7. 
[21] Ridley JH, Edwards IK. Experimental endometriosis in the human. Am J Obstet 
Gynecol. 1958 Oct;76(4):783-9 
[22] Signorile PG, Baldi A. Endometriosis: new concepts in the pathogenesis. Int J Biochem 
Cell Biol. 2010 Jun;42(6):778-80. 
[23] Nisolle M, Donnez J. Peritoneal endometriosis, ovarian endometriosis, and 
adenomyotic nodules of the rectovaginal septum are three different entities. 
Fertility and Sterility. 1997;68:585–95. 
[24] Bulun SE. Endometriosis. New England Journal of Medicine.2009;360:268–79. 
[25] Matsuura K, Ohtake H, Katabuchi H, et al: Coelomic metaplasia theory of 
endometriosis: evidence from in vivo studies and an in vitro experimental model. 
Gynecol Obstet Invest 47(Suppl 1):18, 1999 
[26] Mitchell AO, Hoffman AP, Swartz SE, et al: An unusual occurrence of endometriosis 
in the right groin: a case report and review of the literature. Mil Med 156:633, 
1991 
[27] Pollack R, Gordon PH, Ferenczy A, et al: Perineal endometriosis. A case report.  J 
Reprod Med 35:109, 1990 
[28] Wu MH, Shoji Y, Chuang PC, Tsai SJ. Endometriosis: disease pathophysiology and the 
role of prostaglandins. Expert Rev Mol Med. 2007 Jan 16;9(2):1-20. 
[29] Tsai SJ etal.(2001)Regulation of steroidogenic acute regulatory protein expression and 
progesterone production in endometriotic stromal cells. J Clin Endocrinol Metab 86, 
5765-5773 
[30] Noble LS. etal. (1996) Aromatase expression in endometriosis. J Clin Endocrinol Metab 
81, 174-179 
[31] Guo SW. Epigenetics of endometriosis. Mol Hum Reprod. 2009 Oct;15(10):587-607. 
www.intechopen.com
 
Endometriosis - Basic Concepts and Current Research Trends 24
[32] Seli E, Arici A: Endometriosis: interaction of immune and endocrine systems. Semin 
Reprod Med 21:135, 2003 
[33] Zhang RJ, Wild RA, Ojago JM. Effect of tumor necrosis factor-alpha on adhesion of 
human endometrial stromal cells to peritoneal mesothelia cells: an invitro system. 
Fertil Steril. 1993;59:1196–1201. 
[34] Bullimore DW. Endometriosis is sustained by tumour necrosis factor-alpha. Med 
Hypotheses. 2003; 60:84–88. 
[35] Eisermann J, Gast MJ, Pineda J, Odem RR, Collins JL. Tumor necrosis factor in 
peritoneal fluid of women undergoing laparoscopic surgery. Fertil Steril. 1988; 
50:573–579. 
[36] Calhaz-Jorge C, Costa AP, Barata M, Santos MC, Melo A, Palma-Carlos ML. Tumour 
necrosis factor alpha concentrations in the peritoneal fluid of infertile women with 
minimal or mild endometriosis are lower in patients with red lesions only than in 
patients without red lesions. Hum Reprod. 2000; 15:1256–1260. 
[37] Bedaiwy MA, Falcone T, Sharma RK, et al. Prediction of endometriosis with serum and 
peritoneal fluid markers: a prospective controlled trial. Hum Reprod. 2002; 17:426–
431. 
[38] Kauppila A, Puolakka J, Ylikorkala O. Prostaglandin biosynthesis inhibitors and 
endometriosis. Prostaglandins. 1979; 18:655–661. 
[39] Dawood MY, Khan-Dawood FS, Wilson L Jr. Peritoneal fluid prostaglandins and 
prostanoids in women with endometriosis, chronic pelvic inflammatory disease, 
and pelvic pain. Am J Obstet Gynecol. 1984; 148:391–395. 
[40] Koike H, Egawa H, Ohtsuka T, Yamaguchi M, Ikenoue T, Mori N. Correlation between 
dysmenorrheic severity and prostaglandin production in women with 
endometriosis. Prostaglandins Leukot Essent Fatty Acids. 1992; 46:133–137. 
[41] Matsuzaki  S, Canis  M, Pouly J-L, Wattiez A, Okamura K, Mage G. Cyclooxygenase-2 
expression in deep endometriosis and matched eutopic endometrium. Fertil Sterill. 
2004; 82:1309–15. 
[42] Ota H, Igarashi S, Sasaki M, Tanaka T. Distribution of cycloozygenase-2 in eutopic 
endometrium in endometriosis and adenomyosis. Human Reprod. 2001; 16:561–6. 
[43] Tietjen GE, Bushnell CD, Herial NA, et al. Endometriosis is associated with prevalence 
of comorbid conditions in migraine. Headache. 2007; 47:1069–1078. 
[44] Pasoto SG, Abrao MS, Viana VS, et al. Endometriosis and systemic lupus 
erythematosus: a comparative evaluation of clinical manifestations and serological 
autoimmune phenomena. Am J Reprod Immunol. 2005; 53:85–93. 
[45] Sinaii N, Cleary SD, Ballweg ML, et al. High rates of autoimmune and endocrine 
disorders, fibromyalgia, chronic fatigue syndrome and atopic diseases among 
women with endometriosis: a survey analysis. Hum Reprod. 2002; 17:2715–2724. 
[46] Lamb K, Nichols TR. Endometriosis: a comparison of associated disease histories.  Am J 
Prev Med. 1986; 2:324–329. 
[47] Simpson J, Elias S, Malinak LR, et al. A Heritable aspect of endometriosis: genetic 
studies. Am J Obstet Gynecol. 1980; 137:327–331. 
[48] Di W, Guo SW. The search for genetic variants predisposing women to endometriosis. 
Curr Opin Obstet Gynecol. 2007; 19:395–401. 
www.intechopen.com
 
Endometriosis 25 
[49] Weiss G, Maseela llP,Schott LL, Brockwell SE, Schocken M, Johnston JM. Adenomyosis 
a variant not a disease? Evidence from hysterectomized menopausal women in the 
Study of Women’s Health Across the Nation (SWAN). Fertil Steril 2008 
[50] Zondervan KT, Cardon LR, Kennedy SH. (2002) What makes a good case-control 
study? Design issues for complex traits such as endometriosis. Hum Reprod. 
17,1415-1423 
[51] Foster WG, Agarwal SK. (2002) Environmental contaminants and dietary factors in 
endometriosis. Ann NY Acad Sci. 955, 213-229 
[52] Tsutsumi O. (2005) Assessment of human contamination of estrogenic endocrine-
disrupting chemicals and their risk for human reproduction. J Steroid Biochem Mol 
Biol. 93,325-330 
[53] Missmer SA. etal. (2004) Inutero exposures and the incidence of endometriosis. Fertil 
Steril. 82,1501-1508 
[54] Arisawa K,Takeda H, Mikasa H.(2005) Background exposure to PCDDs/PCDFs/PCBs 
and its potential health effects: a review of epidemiologic studies. J Med Invest. 
52,10-21 
[55] Bock KW, Kohle C. Ah receptor: dioxin-mediated toxic responses as hints to 
deregulated physiologic functions. Biochem Pharmacol. 2006; 72:393–404. 
[56] Puga A,Tomlinson CR, Xia Y. Ah receptor signals cross-talk with multiple 
developmental pathways. Biochem Pharmacol. 2005;69:199–207. 
[57] Ohtake F, Takeyama K, Matsumoto T, Kitagawa H, Yamamoto Y, Nohara K, Tohyama 
C, Krust A, Mimura J, Chambon P. Modulation of estrogen receptor signal ling by 
association with the activated dioxin receptor. Nature 2003;423:545–550. 
[58] Breech LL, Laufer MR: Obstructive anomalies of the female reproductive tract. J Reprod 
Med 44:233, 1999 
[59] Schattman GL, Grifo JA, Birnbaum S: Laparoscopic resection of a non-communicating 
rudimentary uterine horn. A case report. J Reprod Med 40:219, 1995 
[60] Schifrin BS, Erez S, Moore JG.Teen-age endometriosis. Am J Obstet Gynecol. 1973; 
116:973–980. 
[61] Goldstein DP, deCholnoky C, Leventhal JM, et al. New insights into the old problem of 
chronic pelvic pain.  J Pediatr Surg. 1979; 14:675–680. 
[62] Sanfilippo JS, Wakim NG, Schikler KN, et al. Endometriosis in association with uterine 
anomaly. Am J Obstet Gynecol. 1986;154:39–43. 
[63] Dovey S, Sanfilippo J. Endometriosis and the adolescent. Clin Obstet Gynecol. 2010 
Jun;53(2):420-8. 
[64] Houston DE, Noller KL, Melton LJ III, et al: Incidence of pelvic endometriosis in 
Rochester, Minnesota, 1970–1979. Am J Epidemiol 125:959, 1987 
[65] Adamson GD, Pasta DJ. Endometriosis fertility index: the new, validated endometriosis 
staging system. Fertil Steril. 2010 Oct;94(5):1609-15. 
[66] Chapron C, Fauconnier A, Vieira M, Barakat H, Dousset B, Pansini V, Vacher-Lavenu 
MC, Dubuisson JB. Anatomical distribution of deeply infiltrating endometriosis: 
surgical implications and proposition for a classification.  Hum Reprod. 
2003;18(1):157-61. 
www.intechopen.com
 
Endometriosis - Basic Concepts and Current Research Trends 26
[67] Koninckx PR, Meuleman C, Demeyere S, Lesaffre E, Cornillie FJ. Suggestive evidence 
that pelvic endometriosis is a progressive disease, whereas deeply infiltrating 
endometriosis is associated with pelvic pain. Fertil Steril. 1991 Apr;55(4):759-65. 
[68] Arruda MS, Petta CA, Abrão MS, Benetti-Pinto CL. Time elapsed from onset of 
symptoms to diagnosis of endometriosis in a cohort study of Brazilian women. 
Hum Reprod. 2003 Apr;18(4):756-9. 
[69] Hadfield R, Mardon H, Barlow D, Kennedy S. Delay in the diagnosis of 
endometriosis: a survey of women from the USA and the UK. Hum Reprod. 1996 
Apr;11(4):878-80. 
[70] Talley N, Zinsmeister AR, VanDyke C, Melton Lrd (1991) Epidemiology of colonic 
symptoms and the irritable bowel syndrome. Gastroenterology. 101:927–934 
[71] Teke Z, Aytekin FO, Atalay AO, Demirkan NC (2008) Crohn’s disease complicated by 
multiple stenoses and  internal fistulas clinically mimicking small bowel 
endometriosis. World J Gastroenterol 14:146–151 
[72] Onen F (2006) Familial Mediterranean fever. Rheumatol Int 26:489–496 
[73] Poliness A, Lee A, Wein P, Moss S(2004) Pelvic helminthic disease masquerading as 
endometriosis. Aust NZ J Obstet Gynaecol 44:72–74 
[74] Griffin Y, Sudigali V, Jacques A. Radiology of benign disorders of menstruation. Semin 
Ultrasound CT MR. 2010 Oct;31(5):414-32. 
[75] Marcal L, Nothaft MA, Coelho F, Choi H. Deep pelvic endometriosis: MR imaging. 
Abdom Imaging. 2010 Dec;35(6):708-15. Review. 
[76] Catenacci M, Sastry S, Falcone T. Laparoscopic surgery for endometriosis. Clin Obstet 
Gynecol. 2009 Sep;52(3):351-61. 
[77] Luisi S, Lazzeri L, Ciani V, Petraglia F. Endometriosis in Italy: from cost estimates to 
new medical treatment. Gynecol Endocrinol. 2009 Nov;25(11):734-40. 
[78] Bahamondes L, Petta CA, Fernandes A, Monteiro I. Use of the levonorgestrel-releasing 
intrauterine system in women with endometriosis, chronic pelvic pain and 
dysmenorrhea. Contraception 2007;75:S134-9. 
[79] Petta CA, Ferriani RA, Abrao MS, et al. Randomized clinical trial of a levonorgestrel-
releasing intrauterine system and a depot GnRH analogue for the treatment of 
chronic pelvic pain in women with endometriosis. Hum Reprod 2005;20:1993-8. 
[80] Petta CA, Ferriani RA, Abrao MS, et al. A 3-year follow-up of women with 
endometriosis and pelvic pain users of the levonorgestrel-releasing intrauterine 
system. Eur J Obstet Gynecol Reprod Biol 2009;143:128-9. 
[81] 81. Vercellini P, Frontino G, De Giorgi O, Aimi G, Zaina B, Crosignani PG. Comparison 
of a levonorgestrel-releasing intrauterine device versus expectant management 
after conservative surgery for symptomatic endometriosis: a pilot study. Fertil 
Steril 2003;80:305-9. 
[82] Harada T, Taniguchi F. Dienogest: a new therapeutic agent for the treatment of 
endometriosis. Womens Health (Lond Engl). 2010 Jan;6(1):27-35. Review. 
[83] Kitawaki J, Kusuki I, Yamanaka K, Suganuma I. Maintenance therapy with dienogest 
following gonadotropin-releasing hormone agonist treatment for endometriosis-
associated pelvic pain. Eur J Obstet Gynecol Reprod Biol. 2011 Apr 5. [Epub ahead 
of print] 
www.intechopen.com
 
Endometriosis 27 
[84] Bulun SE, Cheng YH, Pavone ME, Yin P, Imir G, Utsunomiya H, Thung S, Xue Q, 
Marsh EE, Tokunaga H, Ishikawa H, Kurita T, Su EJ. 17Beta-hydroxysteroid 
dehydrogenase-2 deficiency and progesterone resistance in endometriosis. Semin 
Reprod Med. 2010 Jan;28(1):44-50. 
[85] Kao LC, Germeyer A, Tulac S, et al. Expression profiling of endometrium from women 
with endometriosis reveals candidate genes for disease-based implantation failure 
and infertility. Endocrinology 2003;144(7):2870–2881 
[86] Burney RO, Talbi S, Hamilton AE, et al. Gene expression analysis of endometrium 
reveals progesterone resistance and candidate susceptibility genes in women with 
endometriosis. Endocrinology 2007;148(8):3814–3826 
[87] Pavao M, Traish AM. Estrogen receptor antibodies: specificity and utility in detection, 
localization and analyses of estrogen receptor a and b. Steroids 2001;66:1–16. 
[88] Speroff L, Darney PF. A clinical guide for contraception. Philadelphia: Lippincott 
Williams & Wilkins; 2005 
[89] Chabbert-Buffet N, Meduri G, Bouchard P, Spitz IM. Selective progesterone receptor 
modulators and progesterone antagonists: mechanisms of action and clinical 
applications. Hum Reprod Update 2005;11:293-307. 
[90] Kupker W, Felberbaum RE, Krapp M, Schill T, Malik E, Diedrich K. Use of GnRH 
antagonists in the treatment of endometriosis. Reprod Biomed Online 2002;5:12–
16. 
[91] Westney OL, Amundsen CL, McGuire EJ (2000) Bladder endometriosis: conservative 
management. J Urol 163:1814–1817 
[92] Vercellini P, Frontino G, Pietropaolo G, Gattei U, Daguati R, Crosignani PG (2004) Deep 
endometriosis: definition, pathogenesis, and clinical management. J Am Assoc 
Gynecol Laparosc 11:153–161 
[93] Kitawaki J. Maintenance therapy for endometriosis. Nippon Rinsho. 2010 Jan;68(1):163-
7. 
[94] Xu XW, Wang LD, Zhu XQ, Yan LZ, Guan YT, Zhu SC, Hu Y. Levonorgestrel-releasing 
intrauterine system and combined oral contraceptives as conservative treatments 
for recurrent ovarian endometriosis: a comparative clinical study. Zhonghua Yi Xue 
Za Zhi. 2011 Apr 19;91(15):1047-50. 
[95] Seracchioli R, Mabrouk M, Manuzzi L, Vicenzi C, Frascà C, Elmakky A, Venturoli S. 
Post-operative use of oral contraceptive pills for prevention of anatomical relapse 
or symptom-recurrence after conservative surgery for endometriosis. Hum Reprod. 
2009 Nov;24(11):2729-35. Epub 2009 Jul 22. 
[96] Bulun SE, Zeitoun KM, Takayama K, Sasano H. Molecular basis for treating 
endometriosis with aromatase inhibitors. Human Reprod Update 2000;6:413–418 
[97] Ota H, Igarashi S, Sasaki M, Tanaka T. Distribution of cyclooxygenase-2 in eutopic and 
ectopic endometrium in endometriosis and adenomyosis. Hum Reprod 
2001;16:561– 566. 
[98] Cobellis L, Razzi S, De Simone S, Sartini A, Fava A, Danero S, Gioffre` W, Mazzini M, 
Petraglia F. The treatment with a COX-2 specific inhibitor is effective in the 
management of pain related to endometriosis. EJOGRB 2004;116: 100–102. 
www.intechopen.com
 
Endometriosis - Basic Concepts and Current Research Trends 28
[99] Kudoh M, Susaki Y, Ideyama Y, et al. Inhibitory effects of a novel aromatase inhibitor, 
YM5 1 I, in rats with experimental endometriosis. J Steroid Biochem Mol Biol 
19971'63:.l 
[100] Takayama K, Zeitoun K, Gunby RT, et al. Treatment of severe postmenopausal 
endometriosis with an aromatase inhibitor. FertiI SteriI 1998: 69: '70 9-i | 3 
[101] Ailawadi RK, Jobanputra S, Kataria M, et al. Treatment of endometriosis and chronic 
pelvic pain with letrozole and norethindrone acetate: a pilot study. Fertil Steril 
2004;81(2):290-296. 
[102] Vercellini P, Crosignani PG, Somigliana E, Berlanda N, Barbara G, Fedele L.Medical 
treatment for rectovaginal endometriosis: what is the evidence? Hum Reprod. 2009 
Oct;24(10):2504-14. 
[103] Jiang H, Shen Y, Wang XG. Current progress of Chinese medicinal treatment of 
endometriosis. Chin J Integr Med. 2010 Jun;16(3):283-8. Epub 2010 Aug 8. 
[104] Dong SW, Wang SZ, Chen LY, Li GH. Effect of Guizhi Fuling Capsule combined with 
interventional ultrasound puncture in treatment of ovarian endometriosis cyst. 
Chin J Integr Tradit West Med Intens Crit Care, 2003;10:313-314. 
[105] Xue XH, lian XL. Effect of 41 cases with endometriosis in treatment of integrative 
medicine. Shaanxi J Tradit Chin Med 2007;28:1194-1195． 
[106] Yu JS. Clinical observation on endometriosis in treatment of integrative medicine. J 
Pract Diagn Therapy 2005;19:383-384. 
[107] Scarpellini F, Sbracia M, Lecchini S, Scarpellini L. Antiangiogenesis treatment with 
thalidomide in endometriosis: a pilot study. Fertil Steril 2002;78:87. 
[108] Cakmak H, Taylor HS. Molecular mechanisms of treatment resistance in 
endometriosis: the role of progesterone-hox gene  interactions. Semin Reprod Med. 
2010 Jan;28(1):69-74. 
[109] Jones PA, Baylin SB. The fundamental role of epigenetic events in cancer. Nat Rev 
Genet 2002;3(6):415–428 
[110] Robertson KD. DNA methylation and human disease. Nat Rev Genet 2005;6(8):597–610 
[111] Roth RS, Punch M, Bachman JE. Psychological Factors in Chronic Pelvic Pain due to 
Endometriosis: A Comparative Study. Gynecol Obstet Invest. 2011 May 21. [Epub 
ahead of print] 
[112] D'Antonio M, Martelli F, Peano S, et al. Ability of recombinant human TNF binding 
protein-1 (r-hTBPl) to inhibit the development of experimentally induced 
endometriosis in rats. "/ Reprod Immunol 2000;48:81-98 
[113] Bruner KL, Matrisian LM, Rodgers WH, et al. Suppression of matrix 
metalloproteinases inhibits establishment of ectopic lesions by human 
endometrium in nude mice. J Clin Invest 1997|'99:2851-2857 
[114] Catenacci M, Sastry S, Falcone T. Laparoscopic surgery for endometriosis.  Clin Obstet 
Gynecol. 2009 Sep;52(3):351-61. 
[115] Koninckx PR, Oosterlynck D, D'Hooghe TM, et al. Deeply infiltrating endometriosis is 
a disease where as mild endometriosis could be considered a non-disease. Ann N Y 
Acad Sci 1994;734:333-341 
www.intechopen.com
 
Endometriosis 29 
[116] Vercellini P, Crosignani PG, Fadini R, et al. A gonadotropin-releasing hormone agonist 
compared with expectant management after conservative surgery for symptomatic 
endometriosis B r J Obstet Gynecol 1999; 106:672471 
[117] Parazzini F Fedele L, Busacca M, et al, Postsurgical treatment of advanced 
endometriosis: results of a randomized clinical trial. Am J Obstet Gynecol 
1994;171:1205-1207. 
[118] Porproa MG, Koninchx PR, Piazze J, et al. Correlation between endometriosis and 
pelvic pain. J Am Assoc Gynecol Laparosc. 1999;6:429–434. 
[119] Pereira RM, Zanatta A, Serafini PC, Redwine D.The feasibility of laparoscopic bowel 
resection performed by a gynaecologist to treat endometriosis. Curr Opin Obstet 
Gynecol. 2010 Aug;22(4):344-53. 
[120] Sanchez Merino JM, Guillan Maquieira C, Garcia Alonso J (2005) Tratamiento de la 
endometriosis vesical. Revisión de la literature española. Arch Esp Urol 58:189–
194 
[121] Bologna RA, Whitmore KE (2001) La endometriosis genitourinaria. In: Ball TP (ed) 
AUA update series, vol 1 (Spanish ed). Medical Trends, Barcelona, pp 21–29 
[122] Leiva O, Ortiz Vico F (1998) Endocervicosis de la vía urinaria: sistema mülleriano 
secundario. In: Patologías excepcionales en Urología. Ed. Luzán, Madrid, pp 11–
43 
[123] Li L, Leng JH, Lang JH, Liu ZF, Sun DW, Zhu L, Fan QB, Shi JH. Diagnosis and 
treatment of ureter endometriosis. Zhonghua Fu Chan Ke Za Zhi. 2011 
Apr;46(4):266-70. 
[124] Marco Camanni, Elena M. Delpiano, Luca Bonino and Francesco Deltetto  Current 
Opinion in Obstetrics and Gynecology 2010, 22:309–314 
[125] Guzick DS,Canis M, Silliman NP, et al. Prediction of pregnancy in infertile women 
based on the ASRM's revised classification for endometriosis. FertiI SteriI 1997; 67 
:822-83 6. 
[126] Ttrmmon IS, Asher LS, Martin JRB, et al. Randomized controlled trial of 
superovulation and insemination for infertility associatedw ith minimal or mild 
endometriosis. Fertil Steril 1991;68:8-12. 
[127] Nuojua HS, Tomas C, Bloigu R, et al. Intrauterine insemination treatment in 
subfertility: an analysis of factors affecting outcome. Hwn Reprod 1999:14:698-
703 
[128] Omland AK, Tanbo T, Dale PO, et al. Artificial insemination by husband in 
unexplained infertility compared with infertility associated with peritoneal 
endometriosis. Hum Reprod 1998;13:2602-2605. 
[129] Simon C, Guttierez A, Vidal A, et al. Outcome of patients with endometriosis in 
assisted reproduction: results from in-vitro fertilization and oocyte donation. Hum 
Reprod 1994;9:725-729. 
[130] Arici A, Oral E, Bukulmez O, et al. The effect of endometriosis on implantation: results 
from the Yale University in vitro fertilization and embryo transfer program. Fertil 
Steril 1996;65:603-6O7. 
www.intechopen.com
 
Endometriosis - Basic Concepts and Current Research Trends 30
[131] Pellicer A, Valbuena D, Bauset C, et al. The follicular endocrine environment in 
stimulated cycles of women with endometriosis: steroid levels and embryo quality. 
Fertil Steril 1998;69:1135-1141 
[132] Redwine DB. Conservativela paroscopice xcisiono f endometriosisb y sharpd 
issection:life table analysis of reoperation and persistent of recurrent disease. Fertil 
Steril 1991;56:628-634 
www.intechopen.com
Endometriosis - Basic Concepts and Current Research Trends
Edited by Prof. Koel Chaudhury
ISBN 978-953-51-0524-4
Hard cover, 490 pages
Publisher InTech
Published online 09, May, 2012
Published in print edition May, 2012
InTech Europe
University Campus STeP Ri 
Slavka Krautzeka 83/A 
51000 Rijeka, Croatia 
Phone: +385 (51) 770 447 
Fax: +385 (51) 686 166
www.intechopen.com
InTech China
Unit 405, Office Block, Hotel Equatorial Shanghai 
No.65, Yan An Road (West), Shanghai, 200040, China 
Phone: +86-21-62489820 
Fax: +86-21-62489821
This book provides an insight into the emerging trends in pathogenesis, diagnosis and management of
endometriosis. Key features of the book include overviews of endometriosis; endometrial angiogenesis, stem
cells involvement, immunological and hormonal aspects related to the disease pathogenesis; recent research
reports on infertility, endometrial receptivity, ovarian cancer and altered gene expression associated with
endometriosis; various predictive markers, and imaging modalities including MRI and ultrasound for efficient
diagnosis; as well as current non-hormonal and hormonal treatment strategies This book is expected to be a
valuable resource for clinicians, scientists and students who would like to have an improved understanding of
endometriosis and also appreciate recent research trends associated with this disease.
How to reference
In order to correctly reference this scholarly work, feel free to copy and paste the following:
Mohammad Reza Razzaghi, Mohammad Mohsen Mazloomfard and Anahita Ansari Jafari (2012).
Endometriosis, Endometriosis - Basic Concepts and Current Research Trends, Prof. Koel Chaudhury (Ed.),
ISBN: 978-953-51-0524-4, InTech, Available from: http://www.intechopen.com/books/endometriosis-basic-
concepts-and-current-research-trends/endometriosis-an-overview
© 2012 The Author(s). Licensee IntechOpen. This is an open access article
distributed under the terms of the Creative Commons Attribution 3.0
License, which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
